Adynxx (ADYX) 10-K 23 Feb 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 17, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 122,154,637
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		27,668,913

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 26,080,384	$ 16,770,879
Accounts receivable, net	2,516,808	968,616
Inventory, net	3,132,538	1,411,748
Prepaid expenses and other current assets	942,015	477,824
Total current assets	32,671,745	19,629,067
Improvements and equipment, net	1,846,809	1,434,027
Intangible assets, net	33,893,694	4,387,293
Goodwill	21,166,412	4,100,295
Other assets	172,868	173,042
Total assets	89,751,528	29,723,724
Current Liabilities:
Accounts payable	2,637,971	1,757,742
Accrued expenses and other current liabilities	3,129,976	2,067,859
Contingent consideration, current	5,146,585	0
Warrant liability	860,651	304,223
Total current liabilities	11,775,183	4,129,824
Long-term debt, net	12,126,390	0
Contingent consideration, long-term	11,881,313	2,931,598
Deferred tax liability	1,468,066	67,000
Other long-term liabilities	75,733	84,071
Total liabilities	$ 37,326,685	$ 7,212,493
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	$ 0	$ 0
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 27,668,913 and 16,202,689 shares issued and outstanding as of December 31, 2015 and 2014, respectively	27,669	16,203
Additional paid-in capital	148,456,703	92,537,742
Accumulated deficit	(96,059,529)	(70,042,714)
Total stockholders' equity	52,424,843	22,511,231
Total liabilities and stockholders' equity	$ 89,751,528	$ 29,723,724

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	45,714,286	45,714,286
Common stock, shares issued	27,668,913	16,202,689
Common stock, shares outstanding	27,668,913	16,202,689

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue, net of returns, allowances and discounts	$ 15,040,929	$ 4,786,131
Cost of revenues	6,049,520	3,270,955
Gross profit	8,991,409	1,515,176
Operating expenses
Selling, general and administrative	35,180,436	26,155,008
Research and product development	715,074	0
Acquisition-related	2,875,586	546,970
Change in fair value of contingent consideration liability	(1,473,700)	231,598
Total operating expenses	37,297,396	26,933,576
Loss from operations	(28,305,987)	(25,418,400)
Other income (expense)
Interest expense	(1,564,990)	(384)
Interest income	41,675	30,739
Change in value of warrant liability	2,094,784	(43,390)
Total other income (expense)	571,469	(13,035)
Net loss before income tax	(27,734,518)	(25,431,435)
Income tax benefit (expense)	1,717,703	(14,000)
Net loss	$ (26,016,815)	$ (25,445,435)
Basic and diluted net loss per common share (in dollars per share)	$ (1.13)	$ (1.74)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	23,061,931	14,628,981

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)		Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013		$ 13,952,696	$ 11,484	$ 58,538,491	$ (44,597,279)
Balance (in shares) at Dec. 31, 2013			11,484,191
Issuance of common stock for the purchase of Choice		1,992,854	$ 274	1,992,580
Issuance of common stock for the purchase of Choice (in shares)			273,368
Issuance of common stock for cash, net of issuance costs		14,372,503	$ 2,139	14,370,364	0
Issuance of common stock for cash, net of issuance costs (in shares)			2,139,287
Exercise of common stock options		1,371,914	$ 307	1,371,607	0
Exercise of common stock options (in shares)			306,403
Exercise of warrants, net of issuance costs of $267,174		5,225,587	$ 977	5,224,610	0
Exercise of warrants, net of issuance costs of $267,174 (in shares)			977,313
Cashless exercise of warrants		0	$ 211	(211)	0
Cashless exercise of warrants (in shares)			211,295
Extinguishment of warrant liability		672,632	$ 0	672,632	0
Issuance of common stock for services		195,338	$ 23	195,315	0
Issuance of common stock for services (in shares)			23,396
Stock-based compensation	[1]	10,841,897	$ 837	10,841,060	0
Stock-based compensation (in shares)	[1]		836,491
Net settlement on vesting of restricted stock awards		(668,755)	$ (98)	(668,657)	0
Net settlement on vesting of restricted stock awards (in shares)			(98,023)
Warrant exchange		0	$ 49	(49)	0
Warrant exchange (in shares)			48,968
Net loss		(25,445,435)	$ 0	0	(25,445,435)
Balance at Dec. 31, 2014		22,511,231	$ 16,203	92,537,742	(70,042,714)
Balance (in shares) at Dec. 31, 2014			16,202,689
Issuance of common stock for the purchase of Choice		15,207,500	$ 3,168	15,204,332	0
Issuance of common stock for the purchase of Choice (in shares)			3,168,229
Issuance of common stock for cash, net of issuance costs		32,196,540	$ 7,582	32,188,958	0
Issuance of common stock for cash, net of issuance costs (in shares)			7,582,418
Exercise of common stock options		332,271	$ 76	332,195	0
Exercise of common stock options (in shares)			75,919
Cashless exercise of warrants		0	$ 9	(9)	0
Cashless exercise of warrants (in shares)			8,970
Extinguishment of warrant liability		31,498	$ 0	31,498	0
Stock-based compensation		8,633,787	$ 720	8,633,067	0
Stock-based compensation (in shares)			720,000
Net settlement on vesting of restricted stock awards		(471,169)	$ (89)	(471,080)	0
Net settlement on vesting of restricted stock awards (in shares)			(89,312)
Net loss		(26,016,815)	$ 0	0	(26,016,815)
Balance at Dec. 31, 2015		$ 52,424,843	$ 27,669	$ 148,456,703	$ (96,059,529)
Balance (in shares) at Dec. 31, 2015			27,668,913
[1]	Includes $307,189 that was part of accrued expenses as of December 31, 2013 and for the year then ended, which was credited to equity upon the issuance of 34,086 restricted common shares during the year ended December 31, 2014.

CONSOLIDATED STATEMENT OF STOC6

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY [Parenthetical] - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities		$ 307,189
Debt Conversion, Converted Instrument, Shares Issued	34,086
Payments of Stock Issuance Costs	$ 602,500
Warrant [Member]
Payments of Stock Issuance Costs	$ 267,174

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Activities
Net loss	$ (26,016,815)	$ (25,445,435)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,866,608	1,080,334
Amortization of deferred lease incentive	(8,338)	(8,337)
Loss on disposal of property and equipment	4,211	0
Deferred income tax (benefit) expense	(1,717,703)	14,000
Provision for doubtful accounts	107,874	0
Provision for inventory obsolescence	58,159	(75,486)
Stock-based compensation expense	8,633,787	10,534,708
Amortization of debt issuance and discount costs	565,225	0
Stock issued for services rendered	0	195,338
Change in value of warrant liability	(2,094,784)	43,390
Fair value adjustment of contingent consideration liability	(1,473,700)	231,598
Changes in operating assets and liabilities:
Accounts receivable	(779,476)	(800,198)
Inventory	(1,437,806)	(437,832)
Prepaid expenses and other current assets	(257,270)	(387,837)
Accounts payable	571,614	937,639
Accrued expenses and other current liabilities	(639,275)	826,659
Net Cash Used in Operating Activities	(21,617,689)	(13,291,459)
Investing Activities
Payment for distribution rights	0	(333,333)
Purchase of improvements and equipment	(426,510)	(6,596)
Acquisition of business, net of cash acquired	(14,947,813)	(1,999,526)
Net Cash Used in Investing Activities	(15,374,323)	(2,339,455)
Financing Activities
Net proceeds from issuance of common stock	32,196,540	14,372,503
Net proceeds from long-term debt	14,243,875	0
Proceeds from the exercise of stock options	332,271	1,371,914
Proceeds from the exercise of warrants	0	5,225,587
Payment of withholding taxes related to stock-based employee compensation	(471,169)	(668,755)
Net Cash Provided by Financing Activities	46,301,517	20,301,249
Net Increase in Cash and Cash Equivalents	9,309,505	4,670,335
Cash and Cash Equivalents - Beginning of period	16,770,879	12,100,544
Cash and Cash Equivalents - End of period	26,080,384	16,770,879
Supplemental Disclosure of Cash Flows Information
Cash paid during the period for Interest	999,750	384
Non-cash investing and financing activities:
Extinguishment of warrant liability due to cashless warrant exercise	31,498	672,632
2013 Bonus awarded in equity	0	307,189
Warrant exchange	0	49
Acquisition of business:
Current assets, excluding cash and cash equivalents	1,424,480	408,548
Improvements and equipment	411,492	0
Intangibles	31,952,000	2,683,000
Goodwill	17,066,117	3,674,326
Liabilities assumed	(2,006,527)	(73,494)
Deferred tax liability	(3,122,249)	0
Contingent consideration	(15,570,000)	(2,700,000)
Issuance of common stock for acquisition	$ (15,207,500)	$ (1,992,854)

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company has a suite of advanced wound care solutions that enable surgeons, clinicians, and wound care practitioners to address some of the challenges presented by chronic and advanced wounds. Principles of Consolidation The accompanying consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates. The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2015 and 2014 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings. Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is a result of product sales and contract manufacturing. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. The allowance for doubtful accounts was approximately $ 175,000 Inventory is valued at the lower of cost or market on a first-in, first-out basis. Reserves for inventory obsolescence are based on expiration date and are utilized to account for slow-moving inventory. Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the shorter of the remaining lease term or estimated useful life. Repairs and maintenance costs are expensed as incurred. Additions and betterments are capitalized. Intangible assets primarily consist of developed technology, customer lists/relationships, non-compete agreements and trade names and trademarks and are amortized ratably over a range of one to seven years which approximates customer attrition rate and technology obsolescence. The Company records goodwill and other indefinite-lived assets in connection with business combinations. Goodwill, which represents the excess of acquisition cost over the fair value of the net tangible and intangible assets of acquired companies, is not amortized. Indefinite-lived assets are stated at fair value as of the date acquired in a business combination. The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment. When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. The first step is to identify the existence of a potential impairment by comparing the fair value of a reporting unit (the estimated fair value of a reporting unit is calculated using a discounted cash flow model) with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, the reporting unit’s goodwill is considered not to be impaired and performance of the second step of the quantitative goodwill impairment test is unnecessary. In 2015, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessment, for one of its reporting units, the Company was required to perform step 1 of the quantitative analysis. The Company’s annual goodwill impairment test during 2015, for this unit, performed under step 1 of the quantitative analysis did not deem an impairment existed as of December 31, 2015. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist for either unit under the qualitative method and/or the quantitative method as of December 31, 2015 or 2014. Asset Impairments The Company reviews for and records impairment losses on long-lived assets (excluding goodwill and other indefinite-lived intangible assets). The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2015, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the year ended December 31, 2015 or 2014. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. The Company also recognizes revenue under a variety of rental programs of the MIST Therapy system. Rental revenue is recognized on a monthly basis of the term of the rental agreement. Deposits received on product orders are recorded as deferred revenue until revenues are generally earned when the products are shipped to customers. Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses, excluding interest and income taxes, are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature. Advertising and marketing costs are expensed as incurred. Advertising expenses for the years ended December 31, 2015 and 2014 were approximately 2.5 1.6 Certain shipping and handling costs are paid for by the Company. Shipping and handling costs amounted to approximately $ 161,000 53,000 All research and product development costs are expensed as incurred. For the year ended December 31, 2015, the Company incurred research and development costs of approximately $ 715,000 Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires the Company to recognize current tax liabilities or receivables for the amount of taxes it estimates are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2015 and 2014. As of December 31, 2015 and December 31, 2014, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required. The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a securities purchase agreement in 2012 and in connection with a credit agreement entered into in 2015. The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions. Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014. The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment. Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of stock options, warrants and non-vested restricted stock, were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive. As of December 31, 2015 2014 Stock options 6,230,549 4,817,660 Warrants 3,372,550 2,675,121 Non-vested restricted stock 691,725 188,149 Total 10,294,824 7,680,930 In January 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”), which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its financial statements. In November 2015, the FASB issued Accounting Standards Update 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), an update to accounting guidance to simplify the presentation of deferred income taxes. The guidance requires an entity to classify all deferred tax liabilities and assets as noncurrent in the balance sheet. The guidance requires an entity to classify all deferred tax liabilities and assets, along with any valuation allowance, as noncurrent in the balance sheet. The guidance is effective for public companies with annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is permitted. The Company has elected to early adopt ASU 2015-17 during the year ended December 31, 2015 with retrospective application. The adoption of ASU 2015-17 did not have a material impact on the Company's consolidated financial statements. In September 2015, the FASB issued Accounting Standards Update 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement Period Adjustments” (“ASU 2015-16”), an update to accounting guidance to simplify the accounting for business combinations. The guidance requires an acquirer to recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The updated guidance eliminates the requirement to retrospectively account for these adjustments and restate prior period financial statements. The standard is effective for annual reporting periods beginning after December 15, 2015, which for the Company will commence with the year beginning January 1, 2016. Prospective application is required. The adoption will have an impact on the Company’s consolidated financial statements if it is the acquirer in a business combination that includes measurement-period adjustments. In July 2015, the FASB issued Accounting Standards Update 2015-11,” Inventory (Topic 330) Simplifying the Measurement of Inventory” (“ASU 2015-11”). Currently, all inventory is measured at the lower of cost or market. ASU 2015-11 changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. The standard is effective for annual reporting periods beginning after December 15, 2015, which for the Company will commence with the year beginning January 1, 2016. Prospective application is required. The Company does not believe the implementation of this standard will have a material impact on the Company’s consolidated financial statements. In April 2015, the FASB issued Accounting Standards Update 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. The Company early-adopted ASU 2015-03 during the year ended December 31, 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 did not have an impact on the Company's consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standard is effective for annual reporting periods beginning after December 15, 2017, which for the Company will commence with the year beginning January 1, 2018. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements. In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015. This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. Acquisitions Acquisition of Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds for an aggregate purchase price of approximately $ 46.3 15.5 0.3 3,168,229 15,570,000 This acquisition complements the Company’s growth strategy aimed at providing a portfolio of advanced wound care solutions. The fair value of this liability is based on future sales projections of MIST Therapy. At the date of acquisition and as of December 31, 2015, the cash flow projection was discounted using a weighted average cost of capital of 12.5 500,000 20 450,000 5.1 10.9 The assets and liabilities of the acquired business were included in the Company’s consolidated balance sheet based upon estimated fair values on the date of acquisition as determined in the purchase price allocation, using available information and making assumptions management believes are reasonable. The consolidated statements of operations include the results of the Celleration’s operations subsequent to the acquisition date. Consideration: Common stock $ 15,207,500 Cash paid 15,476,191 Fair value of contingent consideration 15,570,000 Total consideration 46,253,691 Cash 528,378 Trade receivables 876,590 Inventory 341,143 Other current assets 206,747 Improvements and equipment 411,492 Tradenames 3,601,000 Technology 27,143,000 Customer relationships 1,208,000 Goodwill 17,066,117 Accounts payable (308,615) Accrued expenses and other liabilities (1,697,912) Deferred tax liability (3,122,249) Net assets acquired $ 46,253,691 The Company recorded intangible assets of approximately $ 32.0 27.1 1.2 3.6 17.1 The Company funded the cash portion and related costs of the Celleration acquisition with the net proceeds received under the senior secured term loan described below in Note 9 - Debt. Revenues included in the consolidated statement of operations for the year ended December 31, 2015 from this acquisition for the period subsequent to the closing of the transaction was approximately $ 6.1 During the year ended December 31, 2015, the Company incurred acquisition-related costs related to Celleration of approximately $ 2.9 Acquisition of Choice Therapeutics, Inc. On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. This acquisition complements the Company’s growth strategy aimed at providing a portfolio of advanced wound care solutions. 2.0 2.0 5.0 At the date of acquisition and as of December 31, 2015, the cash flow projection was discounted using a weighted average cost of capital of 15.5 2.0 The decrease in the fair value of the liability during the year ended is due to lower than expected sales of the TheraBond product. For the year ended December 31, 2014, the adjustment resulted in an increase to the Company’s acquisition-related contingent consideration liability of $ 232,000 The 1.0 and $ 2.9 The assets and liabilities of the acquired business were included in the Company’s consolidated balance sheet based upon estimated fair values on the date of acquisition as determined in the purchase price allocation, using available information and making assumptions management believes are reasonable. The consolidated statements of operations include the results of the Choice operations beginning May 6, 2014. Consideration: Common stock $ 1,992,854 Cash paid 2,000,000 Fair value of contingent consideration 2,700,000 Total consideration 6,692,854 Cash 474 Inventory 396,961 Other assets 11,587 Tradenames 111,000 Technology 2,396,000 Customer relationships 176,000 Goodwill 3,674,326 Other liabilities (73,494) Net assets acquired $ 6,692,854 The amortization period of intangible assets acquired ranges from 3 12 3.7 Revenues included in the consolidated statement of operations for the year ended December 31, 2014 from this acquisition for the period subsequent to the closing of the transaction was approximately $ 1.5 136,000 232,000 200,000 Pro Forma Results The following unaudited pro forma financial information summarizes the results of operations for year ended December 31, 2015 and 2014, as if the acquisitions had been completed as of January 1, 2014. The pro forma results were calculated applying the Company’s accounting policies and include the effects of adjustments related to the amortization charges from the acquired intangibles and long-term debt. Years Ended December 31, 2015 2014 Revenues $ 19,130,107 $ 14,165,549 Net loss $ (30,677,311) $ (34,602,957) Net loss per share $ (1.26) $ (1.92)

Inventory

Inventory	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4. Inventory December 31, 2015 2014 Raw materials $ 241,432 $ 197,514 Work in process 227,773 489,431 Finished goods 2,722,586 725,897 Less: Inventory reserve (59,253) (1,094) Total $ 3,132,538 $ 1,411,748

Improvements and Equipment, net

Improvements and Equipment, net	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Improvements and Equipment, net December 31, Useful Life 2015 2014 (Years) Machinery and equipment 10 $ 3,620,658 $ 2,869,453 Office furniture and equipment 3-10 88,208 51,439 Leasehold improvements (A) 253,401 228,021 3,962,267 3,148,913 Less: Accumulated depreciation and amortization (2,115,458) (1,714,886) Improvements and equipment, net $ 1,846,809 $ 1,434,027 (A) Depreciation and amortization expense was $ 421,000 318,000

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets December 31, 2015 Useful Life Gross Accumulated Net Intangible assets subject to amortization: Technology 10 $ 32,539,000 $ (4,057,675) $ 28,481,325 Customer relationships 9-12 1,984,000 (448,893) 1,535,107 Distribution rights 5.27 400,000 (173,071) 226,929 Tradename 3 111,000 (61,667) 49,333 Non-compete 1 208,333 (208,333) - Total intangible assets subject to amortization 35,242,333 (4,949,639) 30,292,694 Indefinite-lived intangible assets: Tradename Indefinite 3,601,000 - 3,601,000 Total indefinite-lived intangible assets 3,601,000 - 3,601,000 Total intangible assets $ 38,843,333 $ (4,949,639) $ 33,893,694 December 31, 2014 Useful Life Gross Accumulated Net Technology 10 $ 5,396,000 $ (1,934,733) $ 3,461,267 Customer relationships 9-12 776,000 (308,871) 467,129 Distribution rights 5.27 400,000 (96,880) 303,120 Tradename 3 111,000 (24,667) 86,333 Non-compete 1 208,333 (138,889) 69,444 $ 6,891,333 $ (2,504,040) $ 4,387,293 Amortization expense attributable to intangible assets for the year ended December 31, 2015 and 2014 was approximately $ 2.4 763,000 Expected Amortization Expense 2016 $ 3,557,446 2017 3,532,779 2018 3,518,804 2019 3,169,256 2020 3,144,256 Thereafter 13,370,153 Total $ 30,292,694

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued Expenses December 31, 2015 2014 Salaries, benefits and incentive compensation $ 2,146,258 $ 1,528,229 Professional fees 701,534 228,426 Royalty fees 51,690 100,537 Deferred revenue 92,374 78,523 Other 138,120 132,144 Total accrued expenses and other current liabilities $ 3,129,976 $ 2,067,859

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2015
Leases, Operating [Abstract]
Leases of Lessee Disclosure [Text Block]	Operating Leases The Company has an obligation for its corporate offices and commercial manufacturing facility located in Langhorne, Pennsylvania through 2026. The remaining minimum lease payments as of December 31, 2015 were $ 2.1 29,000 1.6 Total rent expense was $ 282,000 207,000 2016 $ 376,690 2017 422,197 2018 426,416 2019 430,634 2020 434,852 Thereafter 1,601,659 Total $ 3,692,448

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Instruments [Abstract]
Long-term Debt [Text Block]	9. Debt Senior Secured Term Loan Facility On May 29, 2015, simultaneously with and related to the closing of the Celleration acquisition, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75% is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date approximately 1.3 169,000 In connection with the entry into the Credit Agreement, a five-year warrant (the “Warrant”) to purchase 750,000 0.001 5.5138 approximately 2.7 397,000 The Credit Agreement requires the Company to prepay the outstanding principal amount of the term loan with 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions. days The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000. The Credit Agreement contains customary affirmative and negative covenants and events of default for a secured financing arrangement, including limitations on additional indebtedness, liens, asset sales and acquisitions, among others. In addition to other customary events of default, any termination of that certain License, Marketing and Development Agreement between the Company and CCT, as amended, will constitute an event of default under the Credit Agreement. December 31, 2015 Long-term debt $ 15,500,000 Unamortized debt issuance and discount costs (3,373,610) Long-term debt, net $ 12,126,390

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies License Agreement On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 500,000 600,000 500,000 400,000 497,000 Sorbion Distributor Agreement In September 2013, the Company entered into a distributor agreement (the “Sorbion Agreement”) with Sorbion GmbH & Co KG, pursuant to which the Company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the United States, Canada and Latin America, subject to certain exceptions. The term of the agreement ends on December 31, 2018. Sorbion assigned its rights and obligations of the Sorbion Agreement to BSN Medical, Inc. (“BSN”), an affiliate of Sorbion, in June 2015. In July 2015, the Company entered into an amendment to the Sorbion Agreement with BSN to provide for pricing in U.S. Dollars instead of Euros. In order to maintain its exclusivity, the Company must purchase minimum amounts of product. The Company has met the minimum purchase amount requirement for the 2015 calendar year of $ 1.1 the minimum annual purchase amounts noted below will be converted from Euros to U.S. Dollars with the exchange rate in effect on the last day of the preceding calendar year, provided that the exchange rate is not more than five percent greater or less than the exchange rate from Euros to U.S. Dollars of 1.10. If the exchange rate is five percent greater or less than 1.10, the rate will be rounded as necessary so that it is no more than five percent greater or five percent less. Calendar Year Minimum Annual Purchase Amount 2016 2,500,000 Euros 2017 4,000,000 Euros If the Company fails to purchase products in amounts that meet or exceed the minimum annual purchase amount for a calendar year, it may cure such minimum purchase failure by paying BSN in cash an amount equal to the minimum annual purchase amount for such calendar year less the amount the Company paid to BSN for the products purchased for such calendar year. If the Company does not cure a minimum purchase failure with a makeup payment for a calendar year, BSN may terminate the Company’s exclusivity with respect to the products and grant the Company non-exclusive rights with respect to the products. If the Company does not cure a minimum purchase failure for two subsequent calendar years, BSN may terminate the agreement. The Company will not be required to meet the minimal annual purchase amount if BSN fails to supply the Company with the products in accordance with the agreement. BSN may also terminate the Company’s exclusivity with respect to the products if the Company does not cure a material breach of the agreement within 30 days. The Company has the right to use the trademarks related to the products. The Company has the ability to sell the products under their respective trademarked names and at prices determined by the Company. The Company is eligible for certain discounts with respect to the purchase and shipping of the products if its orders of the products are above certain amounts. Celgene License, Marketing and Development and Supply Agreement In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”), pursuant to which CCT granted the Company an exclusive, royalty-bearing license in its intellectual property for certain placental based products, including ECM, an extracellularmatrix derived from the human placenta, and Biovance®, CCT’s proprietary wound coverings produced from decellularized, dehydrated human amniotic membrane, to develop and commercialize ECM and Biovance in the United States. The Company is required to pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term. The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. In addition, the License Agreement is terminable on a product-by-product basis, and not with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product (“CTM”). In November 2013, the Company also entered into a Supply Agreement (the “Biovance Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States. The Biovance Supply Agreement will be terminated automatically upon the termination of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Biovance Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. On April 10, 2014, the Company and CCT entered into an amendment to the Biovance Supply Agreement in order to amend the pricing schedule. In April 2014, the Company entered into a Supply Agreement (the “ECM Supply Agreement”) with CCT, pursuant to which CCT shall, as soon as reasonably practicable after the date that CCT obtains regulatory clearance or approval in the United States for any of CCT’s extracellular matrix products derived from the human placenta (each an “ECM”), supply and sell to the Company all of the Company’s requirements of ECM, in finished form and final packaging, for exploitation in the United States under the License Agreement. The ECM Supply Agreement will automatically terminate upon the termination or expiration of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the ECM Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. The ECM Supply Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In January 2016, Human Longevity, Inc.’s (“HLI”), a genomics-based, technology-driven company, announced the planned purchase of LifebankUSA and other select assets from CCT. The Company will remain the exclusive commercial partner for the existing pipeline of human placental based products as noted above. Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of December 31, 2015.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Stockholders’ Equity Preferred Stock The Company has authorized 1,000,000 0.001 Common Stock Issuances On April 14, 2014, the Company entered into a securities purchase agreement pursuant to which the Company issued an aggregate of 2,139,287 427,858 10.50 15.0 598,500 4,000 On May 4, 2015, the Company closed an underwritten public offering of 7,582,418 4.55 32.2 2011 Plan The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, restricted stock units (“RSUs”), restricted stock and other awards to employees, directors and others. A total of 1,828,571 150,670 2014 Plan On April 10, 2014 and June 5, 2014, the Company’s Board of Directors and the Company’s shareholders approved the 2014 Long-Term Incentive Plan (the “2014 Plan”), respectively. The 2014 Plan provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. On February 26, 2015 and May 6, 2015, the Company’s Board of Directors and the Company’s shareholders approved an amendment to the 2014 Plan to increase the total number of shares of common stock authorized for issuance under the 2014 Plan by an additional 3,500,000 2,000,000 5,500,000 2,936,655 Stock-Based Compensation Year Ended December 31, 2015 2014 Options $ 5,942,058 $ 7,815,411 Warrants - 210,160 Restricted stock units - 180,715 Restricted stock 2,691,729 2,523,760 Total stock-based compensation $ 8,633,787 $ 10,730,046 For the year ended December 31, 2015, $ 364,000 8.3 200,000 10.5 Restricted Stock The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2015 and 2014: Issuance Grantee Shares Vesting Grant Date Date Type Issued Term Value 01/06/14 Officer 369,395 [1] $ 2,582,072 01/17/14 Consultant 1,107 Immediate 10,007 01/27/14 Consultant 13,000 Immediate 118,300 03/06/14 Employee 8,300 [2] 74,700 03/09/14 Consultant 1,108 Immediate 10,005 03/21/14 Consultant 1,136 Immediate 10,008 04/02/14 Consultant 1,219 Immediate 10,008 05/29/14 Consultant 1,000 Immediate 7,000 06/16/14 Consultant 1,525 Immediate 10,004 06/18/14 Consultant 1,558 Immediate 10,002 07/01/14 Consultant 1,743 Immediate 10,005 2014- Restricted Stock - Total 401,091 $ 2,852,111 02/06/15 Officers 600,000 [3] $ 3,738,000 06/15/15 Officer 120,000 [4] 630,000 2015 - Restricted Stock - Total 720,000 $ 4,368,000 [1] Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter. [2] 2,425 1,725 [3] Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018. [4] Vests in four equal installments, with one-fourth vesting on the date of grant and one-fourth vesting on each of June 15, 2016, June 15, 2017 and June 15, 2018. On March 14, 2014, in connection with the resignation of the chief executive officer of a wholly-owned subsidiary of the Company, the Company accelerated the vesting of 17,688 157,000 As of December 31, 2015, there was $ 2.0 1.6 Number of Weighted Total Grant Non-vested, December 31, 2014 35,376 $ 2.19 $ 77,387 Granted 401,091 $ 7.11 2,852,111 Vested (248,318) $ 6.47 (1,607,402) Forfeited - $ - - Non-vested, December 31, 2014 188,149 $ 7.03 $ 1,322,096 Granted 720,000 $ 6.07 4,368,000 Vested (216,424) $ 6.76 (1,464,071) Forfeited - - - Non-vested, December 31, 2015 691,725 $ 6.11 $ 4,226,025 Warrants See Common Stock Issuances above for details of warrants issued in connection with equity offerings. See Note 9 - Debt – Senior Secured Term Loan Facility for details associated with a warrant issued in connection with debt. On April 11, 2014, the Company entered into a letter agreement with certain of the holders of warrants to purchase shares of the Company’s common stock that were granted pursuant to that certain securities purchase agreement, dated November 18, 2013, by and among the Company and the investors signatory thereto. The Company received approximately $ 5.3 930,313 265,000 2,500 5.69 1.5 During the year ended December 31, 2014, away from exercised warrants discussed above, the Company issued an aggregate of 258,295 400,137 353,137 47,000 199,000 4.24 241,060 3.02 65,362 2.19 93,715 2.0 During the year ended December 31, 2015, the Company issued an aggregate of 8,970 15,999 9,142 2.19 45,000 There were no compensatory warrants issued during the years ended December 31, 2015 and 2014. As of December 31, 2015, there was no unrecognized stock-based compensation expense related to compensatory warrants. Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2013 3,822,557 $ 5.12 Issued 427,858 10.50 Exercised (1,330,450) 5.03 Cancelled (244,844) 7.88 Outstanding, December 31, 2014 2,675,121 $ 5.76 Issued 750,000 5.51 Exercised (15,999) 2.19 Cancelled (36,572) 7.88 Outstanding, December 31, 2015 3,372,550 $ 5.70 3.1 $ - Exercisable, December 31, 2015 3,372,550 $ 5.70 3.1 $ - Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Average Exercisable $ 2.19 92,573 1.8 92,573 3.02 74,286 1.1 74,286 3.50 2,286 1.3 2,286 4.24 780,191 2.4 780,191 4.38 188,444 2.8 188,444 4.81 8,889 2.8 8,889 5.51 750,000 4.4 750,000 5.69 1,040,880 2.9 1,040,880 8.75 7,143 0.2 7,143 10.50 427,858 3.3 427,858 3,372,550 3.1 3,372,550 As of December 31, 2015 and 2014, warrants to purchase an aggregate of 816,287 75,429 5.24 2.19 Stock Options Options - 2014 Grants During 2014, ten-year options to purchase an aggregate of 1,273,520 3.89 9.05 7.00 7.1 736,500 268,000 269,020 Details of the grants with the more significant grant date values are as follows: (1) On January 6, 2014, a ten-year option to purchase 91,520 506,000 6.99 22,800 (2) On March 6, 2014, a ten-year option to purchase 70,000 9.00 210,000 1.5 23,333 Options – 2015 Grants During 2015, ten-year options to purchase an aggregate of 1,905,000 2.38 6.23 8.0 1,818,000 87,000 4,500 90,000 1,810,500 (1) On February 6, 2015, ten-year options to purchase an aggregate of 745,000 3.6 6.23 (2) On May 29, 2015, ten-year options to purchase an aggregate of 455,000 1.8 4.95 440,000 15,000 (3) On August 3, 2015, ten-year options to purchase an aggregate of 270,000 1.0 5.08 Options – Summary Data Year Ended December 31, 2015 2014 Risk free interest rate 1.19% - 2.11 % 1.39% - 2.38 % Expected term (years) 5.00-6.50 5.00 - 10.00 Expected volatility 93.70% - 98.25 % 100.56% - 102.63 % Expected dividends 0.00 % 0.00 % The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to options at annual rates ranging from 0 5 The weighted average estimated fair value of the options granted during the years ended December 31, 2015 and 2014 was $ 4.18 5.60 During the year ended December 31, 2014, the Company issued an aggregate of 306,403 333,876 57,143 276,733 1.4 4.38 252,217 5.47 11,428 6.34 22,857 6.56 47,374 943,000 During the year ended December 31, 2015, the Company issued an aggregate of 75,919 75,919 332,000 4.38 86,000 As of December 31, 2015, there was $ 5.4 1.6 Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2013 4,985,586 $ 6.47 Granted 1,273,520 7.00 Exercised (333,876) 4.86 Forfeited (1,107,570) 7.19 Outstanding, December 31, 2014 4,817,660 $ 6.56 Granted 1,905,000 5.38 Exercised (75,919) 4.38 Forfeited (416,192) 5.96 Outstanding, December 31, 2015 6,230,549 $ 6.26 7.4 $ - Exerciseable, December 31, 2015 3,296,198 $ 6.09 6.2 $ - Options Outstanding Options Exercisable Range of Weighted Outstanding Weighted Average Weighted Exercisable $3.28-$3.99 $ 3.35 512,971 $ 3.36 7.4 407,304 $4.00-$4.99 4.58 1,488,505 4.41 3.8 894,502 $5.00-$5.99 5.28 676,760 5.44 5.9 228,687 $6.00-$6.99 6.59 2,212,796 6.77 7.6 1,045,141 $7.00-$7.99 7.75 31,000 7.75 8.3 10,333 $8.00-$8.99 8.74 780,065 8.74 6.7 540,174 $9.00-$9.99 9.00 264,833 9.00 6.8 113,828 $10.00-$26.69 10.96 263,619 11.01 7.2 56,229 6,230,549 6.2 3,296,198

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes The Company files corporate income tax returns in U.S. federal, state and local jurisdictions, including Pennsylvania, and has tax returns subject to examination by tax authorities generally beginning in the year ended December 31, 2012 and through December 31, 2015. However, to the extent the Company utilizes the For The Years Ended December 31, 2015 2014 Federal: Current $ - $ - Deferred (1,509,375) 10,000 State and local: Current 3,480 - Deferred (211,808) 4,000 Income tax (benefit) expense $ (1,717,703) $ 14,000 For the years ended December 31, 2015 and 2014, the expected tax (benefit) expense based on the statutory rate reconciled with the actual (benefit) expense is as follows: For The Years Ended December 31, 2015 2014 U.S. federal statutory rate 34.0 % 34.0 % State tax rate, net of federal benefit 4.8 % 4.2 % Permanent differences - Change in fair value of warrant liability 2.6 % (0.1) % - Change in fair value of contingent 1.8 % 0.0 % -Acquisition Costs (2.2) % 0.0 % - Other (0.6) % (1.6) % Adjustments to deferred taxes (2.4) % (13.8) % Change in valuation allowance (31.8) % (22.8) % Income tax (benefit) expense 6.2 % (0.1) % As of December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 35,283,725 $ 18,844,000 Stock-based compensation 7,713,496 5,028,000 Accruals 496,396 579,000 Other 252,595 244,000 Total deferred tax assets 43,746,212 24,695,000 Valuation allowance (32,976,841) (24,081,000) Deferred tax assets, net of valuation allowance $ 10,769,371 $ 614,000 Deferred tax liabilities: Property and equipment (409,193) (515,000) Intangible assets (10,360,178) (99,000) Goodwill (1,468,066) (67,000) Total deferred tax liabilities (12,237,437) (681,000) Net deferred tax liabilities $ (1,468,066) $ (67,000) For the years ended December 31, 2015 and 2014, the Company had approximately $ 92,990,000 50,043,000 of federal NOL carryovers, respectively, which substantially begin to expire in 2020 and through 2035. The company also has state NOL carryovers in multiple jurisdictions, including most materially in Pennsylvania, $ 22,876,000 11,648,000 $ 9,812,000 7,850,000 The net operating loss carryovers may be subject to annual limitations under Internal Revenue Code Section 382, and similar state provisions, should there be a greater than 50% ownership change as determined under the applicable income tax regulations. The amount of the limitation would be determined based on the value of the company immediately prior to the ownership change and subsequent ownership changes could further impact the amount of the annual limitation. An ownership change pursuant to Section 382 may have occurred in the past or could happen in the future, such that the NOLs available for utilization could be significantly limited. The Company will perform a Section 382 analysis in the future. On May 29, 2015, the Company acquired Celleration, Inc. (see Note 3 - Acquisitions) and the company has performed a Section 382 study for Celleration, Inc. The amount of federal NOL carryforwards as of December 31, 2015 disclosed above do not include $ 47,945,000 The amount of federal NOL carryforwards as of December 31, 2015 and December 31, 2014 disclosed above do not 2,498,000 Choice NOL carryforwards that the Company has estimated will expire unutilized pursuant to this limitation. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The deferred tax liabilities related to goodwill and to a tradename cannot be used in this determination since both assets are considered to be assets with an indefinite life for financial reporting purposes. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2015 and December 31, 2014 because management has determined that it is more likely than not that these deferred tax assets will not be realized. The valuation allowance increased by $8,895,000 and 6,474,000 the years ended December 31, 2015 and December 31, 2014, respectively, primarily related to increases in NOL carryforwards. The increase during the year ended December 31, 2015 was net of the release of valuation allowances of $1,735,000 million resulting from the acquisition of Celleration in May 2015 for which the Company recorded an income tax benefit.

Related Party

Related Party	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director is a member of the Board of Directors. No payments were made to this vendor in the year ended December 31, 2015. The Company has entered into several agreements with CCT, a wholly-owned subsidiary of Celgene Corporation, as described in Note 10 – Commitments and Contingencies. Celgene is an affiliate of the Company. Two executives of Celgene are on the Company’s board of directors. On May 6, 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product (“CTM”). On May 4, 2015, the Company entered into a securities purchase agreement with Celgene, pursuant to which the Company issued 659,340 shares of common stock at $4.55 per share. On April 14, 2014, the Company entered into a securities purchase agreement with Celgene, pursuant to which the Company issued (i) 714,286 7.00 142,857 10.50 5,000,000 On January 6, 2014, the Company entered into an option cancellation and release agreement with two former directors, pursuant to which each of the parties agreed to cancel options previously granted to purchase 278,096 6.34 9.19 194,667 99,000

Concentration of Risk

Concentration of Risk	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. Concentration of Risk Revenue for the years ended December 31, 2015 and 2014, and accounts receivable as of December 31, 2015 from the Company’s largest customer, a contract manufacturing customer, was as follows: 2015 2014 Customer % of Total Revenue Accounts Receivable % of Total Revenue Accounts Receivable A 10 % 8 % 23 % 9 %

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	15. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. During the year ended December 31, 2014, warrant liabilities to purchase an aggregate of 82,971 673,000 202,000 102.63 1.19 1.22 3.78 3.81 0.00 On December 31, 2014, the Company recomputed the fair value of its remaining warrant liability of warrants to purchase an aggregate of 75,429 304,000 98.25 1.10 2.86 0.00 159,000 During the year ended December 31, 2015, a warrant to purchase an aggregate of 9,142 31,000 4,000 98.25 0.96 2.52 0.00 During the year ended December 31, 2015, in connection with the Credit Agreement, a five-year warrant to purchase 750,000 5.5138 2.7 98.25 1.49 5.00 0.00 On December 31, 2015, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 816,287 861,000 89.95 1.06 1.54 1.86 4.41 0.00 2.1 December 31, 2015 2014 Warrant Liabilities Beginning balance as of January 1, $ 304,223 $ 933,465 Change in fair value of warrant liability (2,094,784) 43,390 Value of warrants issued 2,682,710 - Value of warrants exercised (31,498) (672,632) Ending balance as of December 31, $ 860,651 $ 304,223 December 31, 2015 2014 Contingent Consideration Beginning balance as of January 1, $ 2,931,598 $ - Initial fair value of contingent consideration 15,570,000 2,700,000 Change in fair value of contingent consideration (1,473,700) 231,598 Ending balance as of December 31, $ 17,027,898 $ 2,931,598 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 860,651 Contingent consideration - - 17,027,898 Total liabilities $ - $ - $ 17,888,549 December 31, 2014 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 304,223 Contingent consideration - - 2,931,598 Total liabilities $ - $ - $ 3,235,821 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	16. Defined Contribution Plan The Company maintains the Alliqua, Inc. 401(k) Profit Sharing Plan and Trust (“Plan”) in accordance with the provisions of Section 401(k) of the Internal Revenue Code (“Code”). The Plan covers substantially all full-time employees of the Company. Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code. Under this plan, the Company matches 50 6 75,000

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in the Financial Statements The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2015 and 2014 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is a result of product sales and contract manufacturing. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. The allowance for doubtful accounts was approximately $ 175,000
Inventory, Policy [Policy Text Block]	Inventory Inventory is valued at the lower of cost or market on a first-in, first-out basis. Reserves for inventory obsolescence are based on expiration date and are utilized to account for slow-moving inventory.
Property, Plant and Equipment, Policy [Policy Text Block]	Improvements and Equipment Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the shorter of the remaining lease term or estimated useful life. Repairs and maintenance costs are expensed as incurred. Additions and betterments are capitalized.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets primarily consist of developed technology, customer lists/relationships, non-compete agreements and trade names and trademarks and are amortized ratably over a range of one to seven years which approximates customer attrition rate and technology obsolescence.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Goodwill and Indefinite Life Assets The Company records goodwill and other indefinite-lived assets in connection with business combinations. Goodwill, which represents the excess of acquisition cost over the fair value of the net tangible and intangible assets of acquired companies, is not amortized. Indefinite-lived assets are stated at fair value as of the date acquired in a business combination.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment. When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. The first step is to identify the existence of a potential impairment by comparing the fair value of a reporting unit (the estimated fair value of a reporting unit is calculated using a discounted cash flow model) with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, the reporting unit’s goodwill is considered not to be impaired and performance of the second step of the quantitative goodwill impairment test is unnecessary. In 2015, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessment, for one of its reporting units, the Company was required to perform step 1 of the quantitative analysis. The Company’s annual goodwill impairment test during 2015, for this unit, performed under step 1 of the quantitative analysis did not deem an impairment existed as of December 31, 2015. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist for either unit under the qualitative method and/or the quantitative method as of December 31, 2015 or 2014.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Asset Impairments The Company reviews for and records impairment losses on long-lived assets (excluding goodwill and other indefinite-lived intangible assets). The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2015, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the year ended December 31, 2015 or 2014.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. The Company also recognizes revenue under a variety of rental programs of the MIST Therapy system. Rental revenue is recognized on a monthly basis of the term of the rental agreement. Deposits received on product orders are recorded as deferred revenue until revenues are generally earned when the products are shipped to customers.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Cost of Goods Sold and Selling, General and Administrative Expenses Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses, excluding interest and income taxes, are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	Advertising Expenses Advertising and marketing costs are expensed as incurred. Advertising expenses for the years ended December 31, 2015 and 2014 were approximately 2.5 1.6
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Certain shipping and handling costs are paid for by the Company. Shipping and handling costs amounted to approximately $ 161,000 53,000
Research and Development Expense, Policy [Policy Text Block]	Research and Development All research and product development costs are expensed as incurred. For the year ended December 31, 2015, the Company incurred research and development costs of approximately $ 715,000
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires the Company to recognize current tax liabilities or receivables for the amount of taxes it estimates are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2015 and 2014. As of December 31, 2015 and December 31, 2014, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
Common Stock Purchase Warrant [Policy Text Block]	The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required. The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a securities purchase agreement in 2012 and in connection with a credit agreement entered into in 2015. The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions. Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014. The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of stock options, warrants and non-vested restricted stock, were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive. As of December 31, 2015 2014 Stock options 6,230,549 4,817,660 Warrants 3,372,550 2,675,121 Non-vested restricted stock 691,725 188,149 Total 10,294,824 7,680,930
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In January 2016, the FASB issued Accounting Standards Update 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”), which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its financial statements. In November 2015, the FASB issued Accounting Standards Update 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), an update to accounting guidance to simplify the presentation of deferred income taxes. The guidance requires an entity to classify all deferred tax liabilities and assets as noncurrent in the balance sheet. The guidance requires an entity to classify all deferred tax liabilities and assets, along with any valuation allowance, as noncurrent in the balance sheet. The guidance is effective for public companies with annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is permitted. The Company has elected to early adopt ASU 2015-17 during the year ended December 31, 2015 with retrospective application. The adoption of ASU 2015-17 did not have a material impact on the Company's consolidated financial statements. In September 2015, the FASB issued Accounting Standards Update 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement Period Adjustments” (“ASU 2015-16”), an update to accounting guidance to simplify the accounting for business combinations. The guidance requires an acquirer to recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The updated guidance eliminates the requirement to retrospectively account for these adjustments and restate prior period financial statements. The standard is effective for annual reporting periods beginning after December 15, 2015, which for the Company will commence with the year beginning January 1, 2016. Prospective application is required. The adoption will have an impact on the Company’s consolidated financial statements if it is the acquirer in a business combination that includes measurement-period adjustments. In July 2015, the FASB issued Accounting Standards Update 2015-11,” Inventory (Topic 330) Simplifying the Measurement of Inventory” (“ASU 2015-11”). Currently, all inventory is measured at the lower of cost or market. ASU 2015-11 changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. The standard is effective for annual reporting periods beginning after December 15, 2015, which for the Company will commence with the year beginning January 1, 2016. Prospective application is required. The Company does not believe the implementation of this standard will have a material impact on the Company’s consolidated financial statements. In April 2015, the FASB issued Accounting Standards Update 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. The Company early-adopted ASU 2015-03 during the year ended December 31, 2015, and applied its provisions retrospectively. The adoption of ASU 2015-03 did not have an impact on the Company's consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standard is effective for annual reporting periods beginning after December 15, 2017, which for the Company will commence with the year beginning January 1, 2018. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements. In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015. This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock are as follows: As of December 31, 2015 2014 Stock options 6,230,549 4,817,660 Warrants 3,372,550 2,675,121 Non-vested restricted stock 691,725 188,149 Total 10,294,824 7,680,930

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future. Years Ended December 31, 2015 2014 Revenues $ 19,130,107 $ 14,165,549 Net loss $ (30,677,311) $ (34,602,957) Net loss per share $ (1.26) $ (1.92)
Acquisition of Celleration, Inc [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The Company’s allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition: Consideration: Common stock $ 15,207,500 Cash paid 15,476,191 Fair value of contingent consideration 15,570,000 Total consideration 46,253,691 Cash 528,378 Trade receivables 876,590 Inventory 341,143 Other current assets 206,747 Improvements and equipment 411,492 Tradenames 3,601,000 Technology 27,143,000 Customer relationships 1,208,000 Goodwill 17,066,117 Accounts payable (308,615) Accrued expenses and other liabilities (1,697,912) Deferred tax liability (3,122,249) Net assets acquired $ 46,253,691
Acquisition of Choice Therapeutics, Inc [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The Company’s allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition: Consideration: Common stock $ 1,992,854 Cash paid 2,000,000 Fair value of contingent consideration 2,700,000 Total consideration 6,692,854 Cash 474 Inventory 396,961 Other assets 11,587 Tradenames 111,000 Technology 2,396,000 Customer relationships 176,000 Goodwill 3,674,326 Other liabilities (73,494) Net assets acquired $ 6,692,854

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following: December 31, 2015 2014 Raw materials $ 241,432 $ 197,514 Work in process 227,773 489,431 Finished goods 2,722,586 725,897 Less: Inventory reserve (59,253) (1,094) Total $ 3,132,538 $ 1,411,748

Improvements and Equipment, n28

Improvements and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	December 31, Useful Life 2015 2014 (Years) Machinery and equipment 10 $ 3,620,658 $ 2,869,453 Office furniture and equipment 3-10 88,208 51,439 Leasehold improvements (A) 253,401 228,021 3,962,267 3,148,913 Less: Accumulated depreciation and amortization (2,115,458) (1,714,886) Improvements and equipment, net $ 1,846,809 $ 1,434,027 (A)

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The gross carrying amount and accumulated amortization of intangible assets are as follows: December 31, 2015 Useful Life Gross Accumulated Net Intangible assets subject to amortization: Technology 10 $ 32,539,000 $ (4,057,675) $ 28,481,325 Customer relationships 9-12 1,984,000 (448,893) 1,535,107 Distribution rights 5.27 400,000 (173,071) 226,929 Tradename 3 111,000 (61,667) 49,333 Non-compete 1 208,333 (208,333) - Total intangible assets subject to amortization 35,242,333 (4,949,639) 30,292,694 Indefinite-lived intangible assets: Tradename Indefinite 3,601,000 - 3,601,000 Total indefinite-lived intangible assets 3,601,000 - 3,601,000 Total intangible assets $ 38,843,333 $ (4,949,639) $ 33,893,694 December 31, 2014 Useful Life Gross Accumulated Net Technology 10 $ 5,396,000 $ (1,934,733) $ 3,461,267 Customer relationships 9-12 776,000 (308,871) 467,129 Distribution rights 5.27 400,000 (96,880) 303,120 Tradename 3 111,000 (24,667) 86,333 Non-compete 1 208,333 (138,889) 69,444 $ 6,891,333 $ (2,504,040) $ 4,387,293
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization expense in each of the five years and thereafter subsequent to December 31, 2015 related to the Company’s intangible assets is expected to be as follows: Expected Amortization Expense 2016 $ 3,557,446 2017 3,532,779 2018 3,518,804 2019 3,169,256 2020 3,144,256 Thereafter 13,370,153 Total $ 30,292,694

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following: December 31, 2015 2014 Salaries, benefits and incentive compensation $ 2,146,258 $ 1,528,229 Professional fees 701,534 228,426 Royalty fees 51,690 100,537 Deferred revenue 92,374 78,523 Other 138,120 132,144 Total accrued expenses and other current liabilities $ 3,129,976 $ 2,067,859

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2015
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases in each of the five years and thereafter subsequent to December 31, 2015 are as follows: 2016 $ 376,690 2017 422,197 2018 426,416 2019 430,634 2020 434,852 Thereafter 1,601,659 Total $ 3,692,448

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following: December 31, 2015 Long-term debt $ 15,500,000 Unamortized debt issuance and discount costs (3,373,610) Long-term debt, net $ 12,126,390

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]	If the exchange rate is five percent greater or less than 1.10, the rate will be rounded as necessary so that it is no more than five percent greater or five percent less. Calendar Year Minimum Annual Purchase Amount 2016 2,500,000 Euros 2017 4,000,000 Euros

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes stock-based compensation expense: Year Ended December 31, 2015 2014 Options $ 5,942,058 $ 7,815,411 Warrants - 210,160 Restricted stock units - 180,715 Restricted stock 2,691,729 2,523,760 Total stock-based compensation $ 8,633,787 $ 10,730,046
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2015 and 2014: Issuance Grantee Shares Vesting Grant Date Date Type Issued Term Value 01/06/14 Officer 369,395 [1] $ 2,582,072 01/17/14 Consultant 1,107 Immediate 10,007 01/27/14 Consultant 13,000 Immediate 118,300 03/06/14 Employee 8,300 [2] 74,700 03/09/14 Consultant 1,108 Immediate 10,005 03/21/14 Consultant 1,136 Immediate 10,008 04/02/14 Consultant 1,219 Immediate 10,008 05/29/14 Consultant 1,000 Immediate 7,000 06/16/14 Consultant 1,525 Immediate 10,004 06/18/14 Consultant 1,558 Immediate 10,002 07/01/14 Consultant 1,743 Immediate 10,005 2014- Restricted Stock - Total 401,091 $ 2,852,111 02/06/15 Officers 600,000 [3] $ 3,738,000 06/15/15 Officer 120,000 [4] 630,000 2015 - Restricted Stock - Total 720,000 $ 4,368,000 [1] Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter. [2] 2,425 1,725 [3] Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018. [4] Vests in four equal installments, with one-fourth vesting on the date of grant and one-fourth vesting on each of June 15, 2016, June 15, 2017 and June 15, 2018.
Schedule of Nonvested Share Activity [Table Text Block]	A summary of restricted stock award activity during the years ended December 31, 2015 and 2014 is presented below: Number of Weighted Total Grant Non-vested, December 31, 2014 35,376 $ 2.19 $ 77,387 Granted 401,091 $ 7.11 2,852,111 Vested (248,318) $ 6.47 (1,607,402) Forfeited - $ - - Non-vested, December 31, 2014 188,149 $ 7.03 $ 1,322,096 Granted 720,000 $ 6.07 4,368,000 Vested (216,424) $ 6.76 (1,464,071) Forfeited - - - Non-vested, December 31, 2015 691,725 $ 6.11 $ 4,226,025
Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the warrant activity during the years ended December 31, 2015 and 2014 is presented below: Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2013 3,822,557 $ 5.12 Issued 427,858 10.50 Exercised (1,330,450) 5.03 Cancelled (244,844) 7.88 Outstanding, December 31, 2014 2,675,121 $ 5.76 Issued 750,000 5.51 Exercised (15,999) 2.19 Cancelled (36,572) 7.88 Outstanding, December 31, 2015 3,372,550 $ 5.70 3.1 $ - Exercisable, December 31, 2015 3,372,550 $ 5.70 3.1 $ -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Warrants Outstanding Warrants Exercisable Exercise Price Outstanding Average Exercisable $ 2.19 92,573 1.8 92,573 3.02 74,286 1.1 74,286 3.50 2,286 1.3 2,286 4.24 780,191 2.4 780,191 4.38 188,444 2.8 188,444 4.81 8,889 2.8 8,889 5.51 750,000 4.4 750,000 5.69 1,040,880 2.9 1,040,880 8.75 7,143 0.2 7,143 10.50 427,858 3.3 427,858 3,372,550 3.1 3,372,550
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2015 2014 Risk free interest rate 1.19% - 2.11 % 1.39% - 2.38 % Expected term (years) 5.00-6.50 5.00 - 10.00 Expected volatility 93.70% - 98.25 % 100.56% - 102.63 % Expected dividends 0.00 % 0.00 %
Employee Stock Option [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the years ended December 31, 2015 and 2014 is presented below: Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2013 4,985,586 $ 6.47 Granted 1,273,520 7.00 Exercised (333,876) 4.86 Forfeited (1,107,570) 7.19 Outstanding, December 31, 2014 4,817,660 $ 6.56 Granted 1,905,000 5.38 Exercised (75,919) 4.38 Forfeited (416,192) 5.96 Outstanding, December 31, 2015 6,230,549 $ 6.26 7.4 $ - Exerciseable, December 31, 2015 3,296,198 $ 6.09 6.2 $ -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Range of Weighted Outstanding Weighted Average Weighted Exercisable $3.28-$3.99 $ 3.35 512,971 $ 3.36 7.4 407,304 $4.00-$4.99 4.58 1,488,505 4.41 3.8 894,502 $5.00-$5.99 5.28 676,760 5.44 5.9 228,687 $6.00-$6.99 6.59 2,212,796 6.77 7.6 1,045,141 $7.00-$7.99 7.75 31,000 7.75 8.3 10,333 $8.00-$8.99 8.74 780,065 8.74 6.7 540,174 $9.00-$9.99 9.00 264,833 9.00 6.8 113,828 $10.00-$26.69 10.96 263,619 11.01 7.2 56,229 6,230,549 6.2 3,296,198

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The income tax (benefit) expense consists of the following: For The Years Ended December 31, 2015 2014 Federal: Current $ - $ - Deferred (1,509,375) 10,000 State and local: Current 3,480 - Deferred (211,808) 4,000 Income tax (benefit) expense $ (1,717,703) $ 14,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2015 and 2014, the expected tax (benefit) expense based on the statutory rate reconciled with the actual (benefit) expense is as follows: For The Years Ended December 31, 2015 2014 U.S. federal statutory rate 34.0 % 34.0 % State tax rate, net of federal benefit 4.8 % 4.2 % Permanent differences - Change in fair value of warrant liability 2.6 % (0.1) % - Change in fair value of contingent 1.8 % 0.0 % -Acquisition Costs (2.2) % 0.0 % - Other (0.6) % (1.6) % Adjustments to deferred taxes (2.4) % (13.8) % Change in valuation allowance (31.8) % (22.8) % Income tax (benefit) expense 6.2 % (0.1) %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2015 and 2014, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: As of December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 35,283,725 $ 18,844,000 Stock-based compensation 7,713,496 5,028,000 Accruals 496,396 579,000 Other 252,595 244,000 Total deferred tax assets 43,746,212 24,695,000 Valuation allowance (32,976,841) (24,081,000) Deferred tax assets, net of valuation allowance $ 10,769,371 $ 614,000 Deferred tax liabilities: Property and equipment (409,193) (515,000) Intangible assets (10,360,178) (99,000) Goodwill (1,468,066) (67,000) Total deferred tax liabilities (12,237,437) (681,000) Net deferred tax liabilities $ (1,468,066) $ (67,000)

Concentration of Risk (Tables)

Concentration of Risk (Tables)	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Revenue for the years ended December 31, 2015 and 2014, and accounts receivable as of December 31, 2015 from the Company’s largest customer, a contract manufacturing customer, was as follows: 2015 2014 Customer % of Total Revenue Accounts Receivable % of Total Revenue Accounts Receivable A 10 % 8 % 23 % 9 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis: December 31, 2015 2014 Warrant Liabilities Beginning balance as of January 1, $ 304,223 $ 933,465 Change in fair value of warrant liability (2,094,784) 43,390 Value of warrants issued 2,682,710 - Value of warrants exercised (31,498) (672,632) Ending balance as of December 31, $ 860,651 $ 304,223 December 31, 2015 2014 Contingent Consideration Beginning balance as of January 1, $ 2,931,598 $ - Initial fair value of contingent consideration 15,570,000 2,700,000 Change in fair value of contingent consideration (1,473,700) 231,598 Ending balance as of December 31, $ 17,027,898 $ 2,931,598
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows: December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 860,651 Contingent consideration - - 17,027,898 Total liabilities $ - $ - $ 17,888,549 December 31, 2014 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 304,223 Contingent consideration - - 2,931,598 Total liabilities $ - $ - $ 3,235,821

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,294,824	7,680,930
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	691,725	188,149
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,372,550	2,675,121
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,230,549	4,817,660

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Account Policies [Line Items]
Research and Development Expense, Total	$ 715,074	$ 0
Advertising Expense	2,500,000	1,600,000
Shipping, Handling and Transportation Costs	161,000	$ 53,000
Allowance for Doubtful Accounts Receivable	$ 175,000
Maximum [Member]
Summary Of Significant Account Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Minimum [Member]
Summary Of Significant Account Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year

Acquisitions (Details)

Acquisitions (Details) - USD ($)	May. 05, 2014	May. 29, 2015	Dec. 31, 2015	Dec. 31, 2014
Consideration:
Fair value of contingent consideration			$ 15,570,000	$ 2,700,000
Goodwill			$ 21,166,412	$ 4,100,295
Acquisition of Celleration, Inc [Member]
Consideration:
Common stock		$ 15,207,500
Cash paid		15,476,191
Fair value of contingent consideration		15,570,000
Total consideration		46,253,691
Cash		528,378
Trade receivables		876,590
Inventory		341,143
Other current assets		206,747
Improvements and equipment		411,492
Goodwill		17,066,117
Accounts payable		(308,615)
Accrued expenses and other liabilities		(1,697,912)
Deferred tax liability		(3,122,249)
Net assets acquired		46,253,691
Acquisition of Celleration, Inc [Member] | Trade Names [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		3,601,000
Acquisition of Celleration, Inc [Member] | Technology [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		27,143,000
Acquisition of Celleration, Inc [Member] | Customer Relationships [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 1,208,000
Acquisition of Choice Therapeutics, Inc [Member]
Consideration:
Common stock	$ 1,992,854
Cash paid	2,000,000
Fair value of contingent consideration	2,700,000
Total consideration	6,692,854
Cash	474
Inventory	396,961
Other assets	11,587
Goodwill	3,674,326
Other liabilities	(73,494)
Net assets acquired	6,692,854
Acquisition of Choice Therapeutics, Inc [Member] | Trade Names [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	111,000
Acquisition of Choice Therapeutics, Inc [Member] | Technology [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2,396,000
Acquisition of Choice Therapeutics, Inc [Member] | Customer Relationships [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 176,000

Acquisitions (Details 1)

Acquisitions (Details 1) - Choice Therapeutics, Inc. [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenues	$ 19,130,107	$ 14,165,549
Net loss	$ (30,677,311)	$ (34,602,957)
Net loss per share	$ (1.26)	$ (1.92)

Acquisitions (Details Textual)

Acquisitions (Details Textual) - USD ($)	May. 05, 2014	May. 29, 2015	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenues, Total			$ 15,040,929	$ 4,786,131
Operating Income (Loss)			(28,305,987)	(25,418,400)
Business Combination, Acquisition Related Costs			2,875,586	546,970
Business Combination Contingent Consideration Adjustments to Fair Value				232,000
Amortization of Intangible Assets			2,400,000	200,000
Working Capital		$ 300,000
Business Combination, Contingent Consideration, at Fair Value			15,570,000	2,700,000
Goodwill			$ 21,166,412	4,100,295
Business Combination, Contingent Consideration Arrangements, Description			The Company has agreed to pay contingent consideration of three and one half times revenue from acquired MIST Therapy products in excess of certain revenue targets for theyears ending December 31, 2015 and 2016, payable in equal amounts of cash and the Companys common stock.
Business Combination, Contingent Consideration, Liability, Current			$ 5,146,585	0
Business Combination, Contingent Consideration, Liability, Noncurrent			11,881,313	2,931,598
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(1,473,700)	231,598
Goodwill, Acquired During Period	$ 3,700,000		$ 17,066,117	$ 3,674,326
Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions			3,168,229	273,368
Minimum [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years
Maximum [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Choice Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability	$ 5,000,000
Business Combination, Acquisition Related Costs	2,000,000
Amortization of Intangible Assets	$ 2,000,000
Payments to Acquire Businesses, Gross			$ 2,000,000
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 1,000,000	$ 2,900,000
Fair Value Inputs, Discount Rate			15.50%
Acquisition of Celleration, Inc [Member]
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs			$ 2,900,000
Business Combination Contingent Consideration Adjustments to Fair Value			450,000
Business Acquisition Initial Cash Payment		15,500,000
Business Combination, Contingent Consideration, at Fair Value		15,570,000
Business Combination, Consideration Transferred		46,253,691
Business Combination Acquisition of transaction costs			6,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets			32,000,000
Goodwill		17,066,117
Payments to Acquire Businesses, Gross		15,476,191
Business Combination, Contingent Consideration, Liability, Current			5,100,000
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 10,900,000
Fair Value Inputs, Discount Rate			12.50%
Acquisition of Celleration, Inc [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,208,000
Acquisition of Celleration, Inc [Member] | Other Intangible Assets [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		27,100,000
Acquisition of Celleration, Inc [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 3,600,000
Acquisition of Celleration, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Consideration Paid By Issuing Shares Value			$ 500,000
Stock Issued During Period, Shares, Acquisitions		3,168,229
Acquisition of Celleration, Inc [Member] | UK [Member]
Business Acquisition [Line Items]
Percentage Of Incremental Net Sales			20.00%

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 241,432	$ 197,514
Work in process	227,773	489,431
Finished goods	2,722,586	725,897
Less: Inventory reserve	(59,253)	(1,094)
Total	$ 3,132,538	$ 1,411,748

Improvements and Equipment, n44

Improvements and Equipment, net (Details) - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Machinery and equipment		$ 3,620,658	$ 2,869,453
Office furniture and equipment		88,208	51,439
Leasehold improvements	[1]	253,401	228,021
Property, Plant and Equipment, Gross, Total		3,962,267	3,148,913
Less: Accumulated depreciation and amortization		(2,115,458)	(1,714,886)
Improvements and equipment, net		$ 1,846,809	$ 1,434,027
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		10 years
[1]	Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Improvements and Equipment, n45

Improvements and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$ 421,000	$ 318,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 38,843,333	$ 6,891,333
Accumulated Amortization	(4,949,639)	(2,504,040)
Net Carrying Amount	33,893,694	$ 4,387,293
Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	3,601,000
Accumulated Amortization	0
Net Carrying Amount	3,601,000
Intangible assets subject to amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	35,242,333
Accumulated Amortization	(4,949,639)
Net Carrying Amount	$ 30,292,694
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	7 years
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	10 years	10 years
Gross Amount	$ 32,539,000	$ 5,396,000
Accumulated Amortization	(4,057,675)	(1,934,733)
Net Carrying Amount	28,481,325	3,461,267
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	1,984,000	776,000
Accumulated Amortization	(448,893)	(308,871)
Net Carrying Amount	$ 1,535,107	$ 467,129
Customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	9 years	9 years
Customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years
Distribution rights [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years 3 months 7 days	5 years 3 months 7 days
Gross Amount	$ 400,000	$ 400,000
Accumulated Amortization	(173,071)	(96,880)
Net Carrying Amount	$ 226,929	$ 303,120
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Gross Amount	$ 111,000	$ 111,000
Accumulated Amortization	(61,667)	(24,667)
Net Carrying Amount	49,333	$ 86,333
Tradename [Member] | Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	3,601,000
Accumulated Amortization	0
Net Carrying Amount	$ 3,601,000
Non-compete [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year	1 year
Gross Amount	$ 208,333	$ 208,333
Accumulated Amortization	(208,333)	(138,889)
Net Carrying Amount	$ 0	$ 69,444

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
2,016	$ 3,557,446
2,017	3,532,779
2,018	3,518,804
2,019	3,169,256
2,020	3,144,256
Thereafter	13,370,153
Total	$ 33,893,694	$ 4,387,293

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 2,400,000	$ 200,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 2,146,258	$ 1,528,229
Professional fees	701,534	228,426
Royalty fees	51,690	100,537
Deferred revenue	92,374	78,523
Other	138,120	132,144
Total accrued expenses and other current liabilities	$ 3,129,976	$ 2,067,859

Operating Leases (Details)

Operating Leases (Details)	Dec. 31, 2015USD ($)
Operating Leased Assets [Line Items]
2,016	$ 376,690
2,017	422,197
2,018	426,416
2,019	430,634
2,020	434,852
Thereafter	1,601,659
Total	$ 3,692,448

Operating Leases (Details Textu

Operating Leases (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$ 282,000	$ 207,000
Operating Leases, Future Minimum Payments Due	3,692,448
Manufacturing facility, Langhorne [Member]
Operating Leased Assets [Line Items]
Operating Leases, Future Minimum Payments Due	2,100,000
Corporate office space, Eden Prairie [Member]
Operating Leased Assets [Line Items]
Operating Leases, Future Minimum Payments Due	29,000
Corporate office space, Yardley [Member]
Operating Leased Assets [Line Items]
Operating Leases, Future Minimum Payments Due	$ 1,600,000

Debt (Details)

Debt (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 15,500,000
Unamortized debt issuance and discount costs	(3,373,610)
Long-term debt, net	$ 12,126,390	$ 0

Debt (Details Textual)

Debt (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	May. 29, 2015	May. 04, 2015	Apr. 14, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001		$ 4.55	$ 7
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.5138
Derivative Liability	$ 860,651	$ 304,223				$ 933,465
Amortization of Debt Discount (Premium)	$ 565,225	0
Warrant Expiration Period	five-year warrant
Common Stock Purchased By Warrants Issued	750,000
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	$ 860,651	$ 304,223
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	2,700,000
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs	169,000
Amortization of Debt Discount (Premium)	397,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 15,500,000
Debt Issuance Cost	$ 1,300,000
Debt Instrument, Interest Rate Terms	accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Term	4 years
Debt Instrument, Payment Terms	is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument, Maturity Date, Description	The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000.
Debt Instrument Prepayment Terms	The Credit Agreement requires the Company to prepay the outstanding principal amount of the term loan with 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions.

Commitments and Contingencies54

Commitments and Contingencies (Details)	Dec. 31, 2015EUR (€)
Commitments And Contingencies [Line Items]
2,016	€ 2,500,000
2,017	€ 4,000,000

Commitments and Contingencies55

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Accounts Payable, Current		$ 2,637,971	$ 1,757,742
AIQA Cedar Inc [Member]
Commitments And Contingencies [Line Items]
Accounts Payable, Current		497,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year		500,000
Contractual Obligation, Due in Next Twelve Months		600,000
Royalty Expense		500,000	$ 400,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%
Sorbion Distributor Agreement [Member]
Commitments And Contingencies [Line Items]
Recorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months		$ 1,100,000
Other Commitments, Description		the minimum annual purchase amounts noted below will be converted from Euros to U.S. Dollars with the exchange rate in effect on the last day of the preceding calendar year, provided that the exchange rate is not more than five percent greater or less than the exchange rate from Euros to U.S. Dollars of 1.10. If the exchange rate is five percent greater or less than 1.10, the rate will be rounded as necessary so that it is no more than five percent greater or five percent less.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Share Based Compensation Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 8,633,787	$ 10,730,046
Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	5,942,058	7,815,411
Warrants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	0	210,160
Restricted stock units [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	0	180,715
Restricted stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 2,691,729	$ 2,523,760

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - USD ($)		12 Months Ended
		Dec. 31, 2015		Dec. 31, 2014
Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Jan. 17, 2014
Shares Issued				1,107
Vesting Term				Immediate
Grant Date Value				$ 10,007
Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Jan. 27, 2014
Shares Issued				13,000
Vesting Term				Immediate
Grant Date Value				$ 118,300
Consultant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Mar. 9, 2014
Shares Issued				1,108
Vesting Term				Immediate
Grant Date Value				$ 10,005
Consultant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Mar. 21, 2014
Shares Issued				1,136
Vesting Term				Immediate
Grant Date Value				$ 10,008
Consultant Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Apr. 2, 2014
Shares Issued				1,219
Vesting Term				Immediate
Grant Date Value				$ 10,008
Consultant Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				May 29, 2014
Shares Issued				1,000
Vesting Term				Immediate
Grant Date Value				$ 7,000
Consultant Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Jun. 16, 2014
Shares Issued				1,525
Vesting Term				Immediate
Grant Date Value				$ 10,004
Consultant Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Jun. 18, 2014
Shares Issued				1,558
Vesting Term				Immediate
Grant Date Value				$ 10,002
Consultant Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Jul. 1, 2014
Shares Issued				1,743
Vesting Term				Immediate
Grant Date Value				$ 10,005
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date				Mar. 6, 2014
Shares Issued				8,300
Vesting Term	[1]			-
Grant Date Value				$ 74,700
Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date		Feb. 6, 2015
Shares Issued		600,000
Vesting Term	[2]	-
Grant Date Value		$ 3,738,000
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date		Jun. 15, 2015		Jan. 6, 2014
Shares Issued		120,000		369,395
Vesting Term		-	[3]	-	[4]
Grant Date Value		$ 630,000		$ 2,582,072
Restricted Stock Total [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued		720,000		401,091
Grant Date Value		$ 4,368,000		$ 2,852,111
[1]	2,425 shares vest on both March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.
[2]	Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018.
[3]	Vests in four equal installments, with one-fourth vesting on the date of grant and one-fourth vesting on each of June 15, 2016, June 15, 2017 and June 15, 2018.
[4]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Restricted Stock [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Non-vested, December 31 (in shares)	188,149	35,376
Number of Shares, Granted (in shares)	720,000	401,091
Number of Shares, Vested (in shares)	(216,424)	(248,318)
Number of Shares, Forfeited (in shares)	0	0
Number of Shares, Non-vested, December 31 (in shares)	691,725	188,149
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$ 7.03	$ 2.19
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	6.07	7.11
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	6.76	6.47
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	0	0
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$ 6.11	$ 7.03
Total Grant Date Fair Value, Non-vested, December 31	$ 1,322,096	$ 77,387
Total Grant Date Fair Value, Granted	4,368,000	2,852,111
Total Grant Date Fair Value, Vested	(1,464,071)	(1,607,402)
Total Grant Date Fair Value, Forfeited	0	0
Total Grant Date Fair Value, Non-vested, December 31	$ 4,226,025	$ 1,322,096

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	2,675,121	3,822,557
Number of Warrants, Issued (in shares)	750,000	427,858
Number of Warrants, Exercised (in shares)	(15,999)	(1,330,450)
Number of Warrants, Cancelled (in shares)	(36,572)	(244,844)
Number of Options, Outstanding at End of the period (in shares)	3,372,550	2,675,121
Number of Warrants, Exercisable, December 31, 2015 (in shares)	3,372,550
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 5.76	$ 5.12
Weighted Average Exercise Price, Issued (in dollars per share)	5.51	10.5
Weighted Average Exercise Price, Exercised (in dollars per share)	2.19	5.03
Weighted Average Exercise Price, Cancelled (in dollars per share)	7.88	7.88
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	5.7	$ 5.76
Weighted Average Exercise Price, Exercisable December 31, 2015 (in dollars per share)	$ 5.7
Weighted Average Remaining Life In Years, Outstanding, December 31, 2015 (Years)	3 years 1 month 6 days
Weighted Average Remaining Life In Years, Exercisable, December 31, 2015 (Years)	3 years 1 month 6 days
Intrinsic Value, Outstanding, December 31, 2015	$ 0
Intrinsic Value, Exercisable, December 31, 2015	$ 0

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,372,550
Warrants Exercisable, Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Number of Warrants	3,372,550
Exercise Price Range, 2.19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.19
Warrants Outstanding, Number of Warrants	92,573
Warrants Exercisable, Average Remaining Life In Years	1 year 9 months 18 days
Warrants Exercisable, Number of Warrants	92,573
Exercise Price Range, 3.02 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.02
Warrants Outstanding, Number of Warrants	74,286
Warrants Exercisable, Average Remaining Life In Years	1 year 1 month 6 days
Warrants Exercisable, Number of Warrants	74,286
Exercise Price Range, 3.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.50
Warrants Outstanding, Number of Warrants	2,286
Warrants Exercisable, Average Remaining Life In Years	1 year 3 months 18 days
Warrants Exercisable, Number of Warrants	2,286
Exercise Price Range, 4.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.24
Warrants Outstanding, Number of Warrants	780,191
Warrants Exercisable, Average Remaining Life In Years	2 years 4 months 24 days
Warrants Exercisable, Number of Warrants	780,191
Exercise Price Range, 4.38 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.38
Warrants Outstanding, Number of Warrants	188,444
Warrants Exercisable, Average Remaining Life In Years	2 years 9 months 18 days
Warrants Exercisable, Number of Warrants	188,444
Exercise Price Range, 4.81 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.81
Warrants Outstanding, Number of Warrants	8,889
Warrants Exercisable, Average Remaining Life In Years	2 years 9 months 18 days
Warrants Exercisable, Number of Warrants	8,889
Exercise Price Range, 5.51 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.51
Warrants Outstanding, Number of Warrants	750,000
Warrants Exercisable, Average Remaining Life In Years	4 years 4 months 24 days
Warrants Exercisable, Number of Warrants	750,000
Exercise Price Range, 5.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.69
Warrants Outstanding, Number of Warrants	1,040,880
Warrants Exercisable, Average Remaining Life In Years	2 years 10 months 24 days
Warrants Exercisable, Number of Warrants	1,040,880
Exercise Price Range, 8.75 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 8.75
Warrants Outstanding, Number of Warrants	7,143
Warrants Exercisable, Average Remaining Life In Years	2 months 12 days
Warrants Exercisable, Number of Warrants	7,143
Exercise Price Range, 10.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10.50
Warrants Outstanding, Number of Warrants	427,858
Warrants Exercisable, Average Remaining Life In Years	3 years 3 months 18 days
Warrants Exercisable, Number of Warrants	427,858

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.19%	1.39%
Expected term (years)	5 years	5 years
Expected volatility	93.70%	100.56%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.11%	2.38%
Expected term (years)	6 years 6 months	10 years
Expected volatility	98.25%	102.63%

Stockholders' Equity (Details 6

Stockholders' Equity (Details 6) - Employee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	4,817,660	4,985,586
Number of Options, Granted (in shares)	1,905,000	1,273,520
Number of Options, Exercised (in shares)	(75,919)	(333,876)
Number of Options, Forfeited (in shares)	(416,192)	(1,107,570)
Number of Options, Outstanding at End of the period (in shares)	6,230,549	4,817,660
Number of Options, Exercisable,December 31, 2015 (in shares)	3,296,198
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 6.56	$ 6.47
Weighted Average Exercise Price, Granted (in dollars per share)	5.38	7
Weighted Average Exercise Price, Exercised (in dollars per share)	4.38	4.86
Weighted Average Exercise Price, Forfeited (in dollars per share)	5.96	7.19
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	6.26	$ 6.56
Weighted Average Exercise Price, Exercisable December 31, 2015 (in dollars per share)	$ 6.09
Weighted Average Remaining Life In Years, Outstanding, December 31, 2015 (Years)	7 years 4 months 24 days
Weighted Average Remaining Life In Years, Exercisable, Exercisable, December 31, 2015 (Years)	6 years 2 months 12 days
Intrinsic Value, Outstanding, December 31, 2015	$ 0
Intrinsic Value, Exercisable, December 31, 2015	$ 0

Stockholders' Equity (Details 7

Stockholders' Equity (Details 7)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares) | shares	3,372,550
Options Exercisable, Exercisable Number of Options (in shares) | shares	3,372,550
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares) | shares	6,230,549
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	3,296,198
Exercise Price Range 3.28 - 3.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 3.28
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	3.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 3.35
Options Outstanding, Outstanding Number of Options (in shares) | shares	512,971
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 3.36
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	407,304
Exercise Price Range 4.00 - 4.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 4
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	4.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 4.58
Options Outstanding, Outstanding Number of Options (in shares) | shares	1,488,505
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 4.41
Options Exercisable, Weighted Average Remaining Life in Years (in years)	3 years 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	894,502
Exercise Price Range 5.00 - 5.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 5
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	5.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 5.28
Options Outstanding, Outstanding Number of Options (in shares) | shares	676,760
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 5.44
Options Exercisable, Weighted Average Remaining Life in Years (in years)	5 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	228,687
Exercise Price Range 6.00 - 6.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 6
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	6.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 6.59
Options Outstanding, Outstanding Number of Options (in shares) | shares	2,212,796
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 6.77
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	1,045,141
Exercise Price Range 7.00 - 7.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 7
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	7.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 7.75
Options Outstanding, Outstanding Number of Options (in shares) | shares	31,000
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 7.75
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	10,333
Exercise Price Range 8.00 - 8.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 8
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	8.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 8.74
Options Outstanding, Outstanding Number of Options (in shares) | shares	780,065
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 8.74
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	540,174
Exercise Price Range 9.00 - 9.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 9
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	9.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 9
Options Outstanding, Outstanding Number of Options (in shares) | shares	264,833
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 9
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	113,828
Exercise Price Range 10.00 - 26.69 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	26.69
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 10.96
Options Outstanding, Outstanding Number of Options (in shares) | shares	263,619
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 11.01
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	56,229

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	May. 04, 2015	Oct. 15, 2014	Apr. 14, 2014	Apr. 11, 2014	Mar. 14, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock			142,857				82,971
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						2,000,000
Share-based Compensation, Total						$ 8,633,787	$ 10,534,708
Stock Issued During Period, Shares, New Issues	659,340		714,286
Proceeds from Issuance of Common Stock	$ 32.2					32,196,540	14,372,503
Payments of Stock Issuance Costs						2,303,461	602,500
Proceeds from Warrant Exercises						$ 0	$ 5,225,587
Preferred Stock, Shares Authorized						1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001
Exercise Price Of Warrants			$ 10.50
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants			$ 15,000,000
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 364,000	$ 200,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense						$ 8,300,000	$ 10,500,000
Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,828,571
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						150,670
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						5,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						2,936,655
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized						3,500,000
Vesting Date March 6, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						2,425
Vesting Date April 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						2,425
Vesting Date April 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						1,725
Vesting Date April 1, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						1,725
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock			427,858
Stock Issued During Period, Shares, New Issues	7,582,418		2,139,287			7,582,418	2,139,287
Exercise Price Of Warrants			$ 10.50
Sale of Stock, Price Per Share	$ 4.55
5.69 Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				1,500,000
Investment Warrants, Exercise Price				$ 5.69
Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs		$ 598,500
CEO of Subsidiary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					17,688
Share-based Compensation, Total							$ 157,000
Escrow Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs		$ 4,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total						$ 2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						216,424	248,318
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition						1 year 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						720,000	401,091
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
Award Date January 6, 2014 [Member] | Vesting Year Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						22,800
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock						15,999
Stock Issued During Period Shares Warrants Exercised							258,295
Number Of Warrants To Purchase Common Stock Exercised						8,970	400,137
Warrants Exercised, Intrinsic Value						$ 45,000	$ 2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						750,000	427,858
Investment Warrants, Exercise Price						$ 2.19
Stock Issued During Period, Shares, New Issues				930,313
Proceeds from Warrant Exercises				$ 5,300,000
Warrant [Member] | Cashless Excisable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised							353,137
Warrant [Member] | Excisable in Cash [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised							47,000
Proceeds from Warrant Exercises							$ 199,000
Warrant [Member] | 3.02 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised							65,362
Investment Warrants, Exercise Price							$ 3.02
Warrant [Member] | 4.24 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised							241,060
Investment Warrants, Exercise Price							$ 4.24
Warrant [Member] | 2.19 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised							93,715
Investment Warrants, Exercise Price							$ 2.19
Warrant [Member] | Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs				265,000
Warrant [Member] | Escrow Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs				$ 2,500

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Federal:
Current	$ 0	$ 0
Deferred	(1,509,375)	10,000
State and local:
Current	3,480	0
Deferred	(211,808)	4,000
Income tax (benefit) expense	$ (1,717,703)	$ 14,000

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
U.S. federal statutory rate	34.00%	34.00%
State tax rate, net of federal benefit	4.80%	4.20%
Permanent differences
- Change in fair value of warrant liability	2.60%	(0.10%)
- Change in fair value of contingent	1.80%	0.00%
-Acquisition Costs	(2.20%)	0.00%
- Other	(0.60%)	(1.60%)
Adjustments to deferred taxes	(2.40%)	(13.80%)
Change in valuation allowance	(31.80%)	(22.80%)
Income tax (benefit) expense	6.20%	(0.10%)

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 35,283,725	$ 18,844,000
Stock-based compensation	7,713,496	5,028,000
Accruals	496,396	579,000
Other	252,595	244,000
Total deferred tax assets	43,746,212	24,695,000
Valuation allowance	(32,976,841)	(24,081,000)
Deferred tax assets, net of valuation allowance	10,769,371	614,000
Deferred tax liabilities:
Property and equipment	(409,193)	(515,000)
Intangible assets	(10,360,178)	(99,000)
Goodwill	(1,468,066)	(67,000)
Total deferred tax liabilities	(12,237,437)	(681,000)
Net deferred tax liabilities	$ (1,468,066)	$ (67,000)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Operating Loss Carryforwards Expiration Year	2020 and through 2035
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 8,895,000	$ 6,474,000
Acquisition of Celleration, Inc [Member]
Income Taxes [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	1,735,000,000,000
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	92,990,000	50,043,000
Domestic Tax Authority [Member] | Acquisition of Celleration, Inc [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	47,945,000
Domestic Tax Authority [Member] | Choice Therapeutics, Inc. [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	2,498,000	2,498,000
State and Local Jurisdiction [Member] | Pennsylvania [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	22,876,000	11,648,000
State and Local Jurisdiction [Member] | Florida [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 9,812,000	$ 7,850,000

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	May. 04, 2015	Apr. 14, 2014	Dec. 31, 2014	Dec. 31, 2015
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues	659,340	714,286
Warrants To Purchase Common Stock		142,857	82,971
Exercise Price Of Warrants		$ 10.50
Proceeds From Issuance Of Common stock And Warrants		$ 5,000,000
Warrants Term		5 years
Common Stock, Par or Stated Value Per Share	$ 4.55	$ 7	$ 0.001	$ 0.001

Concentration of Risk (Details)

Concentration of Risk (Details) - Customer A [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	23.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	8.00%	9.00%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 304,223	$ 933,465
Initial fair value of contingent consideration	15,570,000	2,700,000
Change in fair value	(2,094,784)	43,390
Value of warrants issued	2,682,710	0
Value of warrants exercised	(31,498)	(672,632)
Ending balance	860,651	304,223
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	2,931,598	0
Initial fair value of contingent consideration	15,570,000	2,700,000
Change in fair value	(1,473,700)	231,598
Ending balance	$ 17,027,898	$ 2,931,598

Fair Value Measurement (Detai72

Fair Value Measurement (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Liabilities:
Warrant liabilities	$ 860,651	$ 304,223	$ 933,465
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	860,651	304,223
Contingent consideration	17,027,898	2,931,598
Total liabilities	$ 17,888,549	$ 3,235,821

Fair Value Measurement (Detai73

Fair Value Measurement (Details Textual) - USD ($)	Apr. 14, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate			98.25%
Fair Value Assumptions, Risk Free Interest Rate			1.10%
Fair Value Assumptions, Expected Term			2 years 10 months 10 days
Fair Value Assumptions, Expected Dividend Rate			0.00%
Warrants To Purchase Common Stock	142,857		82,971
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)		$ 2,100,000	$ 202,000
Derivative Liability		$ 860,651	304,223	$ 933,465
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.5138
Common Stock Purchased By Warrants Issued		750,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ 31,498	672,632
Fair Value Adjustment of Warrants		$ (2,094,784)	$ 43,390
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock		9,142
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ 31,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate			102.63%
Fair Value Assumptions, Expected Dividend Rate			0.00%
Warrants To Purchase Common Stock			75,429
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)		4,000	$ 159,000
Derivative Liability		$ 860,651	$ 304,223
Fair Value, Inputs, Level 3 [Member] | Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.25%
Fair Value Assumptions, Risk Free Interest Rate		0.96%
Fair Value Assumptions, Expected Term		2 years 6 months 7 days
Fair Value Assumptions, Expected Dividend Rate		0.00%
Warrants To Purchase Common Stock			304,000
Fair Value, Inputs, Level 3 [Member] | Credit Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.25%
Fair Value Assumptions, Risk Free Interest Rate		1.49%
Fair Value Assumptions, Expected Term		5 years
Fair Value Assumptions, Expected Dividend Rate		0.00%
Derivative Liability		$ 2,700,000
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		89.95%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Warrants To Purchase Common Stock		816,287
Derivative Liability		$ 861,000
Fair Value, Inputs, Level 3 [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			1.22%
Fair Value Assumptions, Expected Term			3 years 9 months 22 days
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		1.06%
Fair Value Assumptions, Expected Term		1 year 10 months 10 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			1.19%
Fair Value Assumptions, Expected Term			3 years 9 months 11 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		1.54%
Fair Value Assumptions, Expected Term		4 years 4 months 28 days

Defined Contribution Plan (Deta

Defined Contribution Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Description of Defined Contribution Pension and Other Postretirement Plans	Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code.
Defined Contribution Plan, Administrative Expenses		$ 0
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	50.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 75,000